Antibodies to matrix metalloproteinase 9
AssigneeGilead Biologics, Inc.
InventorsVictoria Smith, Scott Alan McCauley
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).
Claims16
An isolated antibody or antigen binding fragment thereof that binds matrix metalloproteinase 9 (MMP9), said antibody or antigen binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable (VH) domain, and the light chain comprises a light chain variable (VL) domain;
- wherein the VH domain comprises a complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO:
- 34, a CDR-H-12 comprising the amino acid sequence set forth in SEQ ID NO:
- 35, and a CDR-H3 comprising the amino acid sequence set forth in SEQ. ID NO:
- 36;
- and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:
- 37, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:
- 38, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:
- 39.
An isolated nucleic acid comprising a nucleotide sequence encoding an antibody or antigen binding fragment thereof that binds matrix metalloproteinase 9 (MMP9), said antibody or antigen binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable (VH) domain, and the light chain comprises a light chain variable (VL) domain:
- wherein the VH domain comprises a complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO:
- 34a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:
- 35, and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:
- 36:
- and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:
- 37, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:
- 38and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:
- 39.
Dependencies are inferred from the claim text.